Who Paid My Doc
Jimmy Julia-Martinez
Urogynecology and Reconstructive Pelvic Surgery Guaynabo, PR Medical Doctor
NPI 1972512606 CMS profile 618634
101 Ave San Patricio, Maramar Plaza Suite 1090, Guaynabo, PR 00968
General payments
$4,809
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$2,819
Through program year 2025, Jimmy Julia-Martinez of Guaynabo, PR is reported in the CMS Open Payments database as having received $4,809 across 81 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,819 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 62nd percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,828 | 12 | |
| 2024 | General | $186 | 6 | |
| 2023 | General | $258 | 9 | |
| 2022 | General | $76 | 1 | |
| 2021 | General | $1,861 | 12 | |
| 2020 | General | $208 | 16 | |
| 2019 | General | $391 | 25 |
Beside peers
- Jimmy Julia-Martinez
- Urogynecology and Reconstructive Pelvic Surgery median
- Middle half of Urogynecology and Reconstructive Pelvic Surgery
- National median
In program year 2025, general payments to Jimmy Julia-Martinez were reported at $1,828. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.
Show as a table
| Year | Jimmy Julia-Martinez | Urogynecology and Reconstructive Pelvic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $391 | $358 | $132–$1,270 | $163 |
| 2020 | $208 | $198 | $86–$642 | $114 |
| 2021 | $1,861 | $361 | $118–$1,182 | $132 |
| 2022 | $76 | $410 | $128–$1,175 | $149 |
| 2023 | $258 | $434 | $152–$1,344 | $160 |
| 2024 | $186 | $494 | $193–$1,331 | $164 |
| 2025 | $1,828 | $412 | $133–$1,300 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 13 drugsPart D claims
1,723
Drug cost
$332,373
Branded share of claims
83.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Myrbetriq Mirabegron | Brand | 326 | $161,672 | |
| Premarin Estrogens, Conjugated | Brand | 252 | $111,709 | |
| Elmiron Pentosan Polysulfate Sodium | Brand | 22 | $22,524 | |
| Tolterodine Tartrate Er Tolterodine Tartrate | Brand | 311 | $18,906 | |
| Estradiol | Generic | 84 | $6,839 | |
| Oxybutynin Chloride Er Oxybutynin Chloride | Brand | 245 | $4,576 | |
| Nitrofurantoin Nitrofurantoin Macrocrystal | Brand | 63 | $2,240 | |
| Clobetasol Propionate | Generic | 68 | $1,526 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 124 | $832 | |
| Tramadol Hcl-Acetaminophen Tramadol Hcl/Acetaminophen | Brand | 91 | $725 |
The 10 drugs with the highest cost, of 13 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 21 billing codesPaid by Medicare
$31,399
Medicare patients
75
Services billed
371
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 64% | |
| Diabetes | 57% | |
| Chronic kidney disease | 32% | |
| Osteoporosis | 29% | |
| Depression | 25% | |
| Heart failure | 21% | |
| Ischemic heart disease | 19% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
81 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Urogynecology and Reconstructive Pelvic Surgery in Puerto Rico
Miguel Vazquez Guzman
Urogynecology and Reconstructive Pelvic Surgery · Hato Rey, PR
Shayan Khorsandi
Urogynecology and Reconstructive Pelvic Surgery · Vega Baja, PR
Darlene Vargas Maldonado
Urogynecology and Reconstructive Pelvic Surgery · San Juan, PR
Fidel Santos Santos
Urogynecology and Reconstructive Pelvic Surgery · San Juan, PR
Daniela Carlos Pons
Urogynecology and Reconstructive Pelvic Surgery · Guaynabo, PR
Related records
Urogynecology and Reconstructive Pelvic Surgery in Puerto Rico
Practitioners in the same specialty and state, ranked by reported value.
All Urogynecology and Reconstructive Pelvic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Puerto Rico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.